Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 1/20 | 1.00 |
| ▸ | ADRA2B | P18089 | 1/20 | 1.00 |
| ▸ | ADRA2C | P18825 | 1/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.66 |
| ▸ | MEN1 | O00255 | 2/20 | 0.66 |
| ▸ | MAPT | P10636 | 5/20 | 0.64 |
| ▸ | TSHR | P16473 | 1/20 | 0.62 |
| ▸ | IGF1R | P08069 | 1/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.57 |
| ▸ | GFER | P55789 | 1/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dropropizine SCHEMBL8379428 | 1.00 | ADRA2A (1.00) | ADRA2AADRA2BADRA2CKMT2AMEN1 | |
| Levodropropizine SCHEMBL29043 | 1.00 | ADRA2A (1.00) | ADRA2AADRA2BADRA2CKMT2AMEN1 | |
| Dropropizine SCHEMBL27495915 | 0.98 | ADRA2A (0.97) | ADRA2AADRA2BADRA2CKMT2AMEN1 | |
| Dropropizine SCHEMBL10445730 | 0.91 | ADRA2A (0.83) | ADRA2AADRA2BADRA2CKMT2AMEN1 | |
| Dropropizine SCHEMBL10445733 | 0.90 | ADRA2A (0.81) | ADRA2AADRA2BADRA2CKMT2AMEN1 | |
| Dropropizine SCHEMBL10445975 | 0.90 | ADRA2A (0.81) | ADRA2AADRA2BADRA2CKMT2AMEN1 | |
| Dropropizine SCHEMBL10446140 | 0.90 | ADRA2A (0.81) | ADRA2AADRA2BADRA2CKMT2AMEN1 | |
| Dropropizine SCHEMBL10446134 | 0.90 | ADRA2A (0.81) | ADRA2AADRA2BADRA2CKMT2AMEN1 | |
| Dropropizine SCHEMBL10445732 | 0.90 | ADRA2A (0.81) | ADRA2AADRA2BADRA2CKMT2AMEN1 | |
| Dropropizine SCHEMBL10445734 | 0.85 | ADRA2A (0.72) | ADRA2AADRA2BADRA2CKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 802 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250255781-A1 | PROCESSES FOR PREPARATION OF 3-D PRINTED PHARMACEUTICAL PRODUCTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-08-14 | — | — | US | claimed |
| US-12296043-B2 | Liquisoft capsules | PATHEON SOFTGELS INC. (US) | 2025-05-13 | — | — | US | claimed |
| EP-4510999-A1 | PROCESSES FOR PREPARATION OF 3-D PRINTED PHARMACEUTICAL PRODUCTS | Bristol-Myers Squibb Company (US) | 2025-02-26 | — | — | EP | claimed |
| US-20240165020-A1 | LIQUISOFT CAPSULES | PATHEON SOFTGELS INC (US) | 2024-05-23 | — | — | US | claimed |
| EP-4360653-A2 | LIQUISOFT CAPSULES | Patheon Softgels Inc. (US) | 2024-05-01 | — | — | EP | claimed |
| US-20240082176-A1 | DROPROPIZINE IN COMBINATION WITH AMBROXOL IN THE DOSAGE FORM OF SYRUP AND TABLETS | PRODUCTOS FARMACEUTICOS, S.A. DE C.V. (MX) | 2024-03-14 | — | — | US | claimed |
| US-11872307-B2 | Liquisoft capsules | PATHEON SOFTGELS INC. (US) | 2024-01-16 | — | — | US | claimed |
| EP-3682872-B1 | LIQUISOFT CAPSULES | PATHEON SOFTGELS INC (US) | 2024-01-03 | — | — | EP | claimed |
| US-20230414575-A1 | MK2 ACTIVATING COMPOUNDS FOR USE IN TREATING VASCULAR LEAK AND ENDOTHELIAL BARRIER DISORDERS | AKTTYVA THERAPEUTICS INC (US) | 2023-12-28 | — | — | US | claimed |
| WO-2023205619-A1 | PROCESSES FOR PREPARATION OF 3-D PRINTED PHARMACEUTICAL PRODUCTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-10-26 | — | — | WO | claimed |
| WO-1994020449-A1 | SALTS OF 2-(3-BENZOYLPHENYL)PROPIONIC ACID WITH ACHIRAL AND CHIRAL ORGANIC BASES AND PHARMACEUTICAL COMPOSITIONS THEREOF | DOMPE'FARMACEUTICI SPA (IT) | 1994-09-15 | — | — | WO | claimed |
| US-5087698-A | Using L(+)tartaric acid | DOMPE' FARMACEUTICI S.P.A. (IT) | 1992-02-11 | — | — | US | claimed |
| EP-0409044-A2 | A process for the optical resolution of dropropizine | DOMPE' FARMACEUTICI S.p.A. (IT) | 1991-01-23 | — | — | EP | claimed |
| EP-0147847-B1 | OPTICALLY ACTIVE COMPOUNDS WITH ANTITUSSIVE AND CENTRAL SEDATIVE ACTIVITY, A PROCESS FOR THE PREPARATION THEREOF AND COMPOSITIONS CONTAINING THE SAME | DOMPE' FARMACEUTICI S.p.A. (IT) | 1990-03-07 | — | — | EP | claimed |
| EP-0349066-A1 | Preparation of enantiomers of dropropizine | DSM N.V. (NL) | 1990-01-03 | — | — | EP | claimed |
| EP-0348713-A1 | (R,S)-3-(4-phenyl-1-piperazinyl)-1,2-propanediol salts | DOTT. FORMENTI S.P.A. INDUSTRIA CHIMICA E FARMACEUTICA (IT) | 1990-01-03 | — | — | EP | claimed |
| US-4764515-A | REDUCED SIDE EFFECTS | DOMPE' FARMACEUTICI S.P.A. (IT) | 1988-08-16 | — | — | US | claimed |
| US-4699911-A | Levo and dextro dropropizine having antitussive activity | DOMPE' FARMACEUTICI S.P.A. (IT) | 1987-10-13 | — | — | US | claimed |
| EP-0156331-A2 | Benzofuran derivatives, processes for preparing the same and antihypertensive agents containing the same | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 1985-10-02 | — | — | EP | claimed |
| EP-0147847-A2 | Optically active compounds with antitussive and central sedative activity, a process for the preparation thereof and compositions containing the same | DOMPE' FARMACEUTICI S.p.A. (IT) | 1985-07-10 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240082176-A1 | DROPROPIZINE IN COMBINATION WITH AMBROXOL IN THE DOSAGE FORM OF SYRUP AND TABLETS | QDPR, IL5, CYP3A5 | ADRA2A 186/4885ADRA2B 271/4885ADRA2C 51/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.